Journal Article
. 2011 Aug;14(1).
doi: 10.4048/jbc.2011.14.1.33.

The 70-gene prognostic signature for korean breast cancer patients

Kuk Young Na 1 Ku Sang Kim  Jeong Eon Lee  Hee Jeong Kim  Jung-Hyun Yang  Sei-Hyun Ahn  Byung-In Moon  Ra Mi Kim  Si Mon Ko  Yong Sik Jung  
Affiliations
  • PMID: 21847392
  •     21 References
  •     8 citations

Abstract

Purpose: A 70-gene prognostic signature has prognostic value in patients with node-negative breast cancer in Europe. This diagnostic test known as "MammaPrint™ (70-gene prognostic signature)" was recently validated and implementation was feasible. Therefore, we assessed the 70-gene prognostic signature in Korean patients with breast cancer. We compared the risk predicted by the 70-gene prognostic signature with commonly used clinicopathological guidelines among Korean patients with breast cancer. We also analyzed the 70-gene prognostic signature and clinicopathological feature of the patients in comparison with a previous validation study.

Methods: Forty-eight eligible patients with breast cancer (clinical T1-2N0M0) were selected from four hospitals in Korea. Fresh tumor samples were analyzed with a customized microarray for the 70-gene prognostic signature. Concordance between the risk predicted by the 70-gene prognostic signature and risk predicted by commonly used clinicopathological guidelines (St. Gallen guidelines, National Institutes of Health [NIH] guideline, and Adjuvant! Online) was evaluated.

Results: Prognosis signatures were assessed in 36 patients. No significant differences were observed in the clinicopathological features of patients compared with previous studies. The 70-gene prognosis signature identified five (13.9%) patients with a low-risk prognosis signature and 31 (86.1%) patients with a high-risk prognosis signature. Clinical risk was concordant with the prognosis signature for 29 patients (80.6%) according to the St. Gallen guidelines; 30 patients (83.4%) according to the NIH guidelines; and 23 patients (63.8%) according to the Adjuvant! Online. Our results were different from previous validation studies in Europe with about a 40% low-risk prognosis and about a 60% high-risk prognosis. The high incidence in the high-risk group was consistent with data in Japan.

Conclusion: The results of 70-gene prognostic signature of Korean patients with breast cancer were somewhat different from those identified in Europe. This difference should be studied as whether there is a gene disparity between Asians and Europeans. Further large-scale studies with a follow-up evaluation are required to assess whether the use of the 70-gene prognostic signature can predict the prognosis of Korean patients with breast cancer.

Keywords: Breast neoplasms; Gene expression profiling; Korea.

National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773285
Review.
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
Ben S Wittner, Dennis C Sgroi, +9 authors, Sridhar Ramaswamy.
Clin Cancer Res, 2008 May 17; 14(10). PMID: 18483364    Free PMC article.
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Stella Mook, Marjanka K Schmidt, +10 authors, TRANSBIG Consortium.
Breast Cancer Res Treat, 2008 Jul 29; 116(2). PMID: 18661261
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Marieke E Straver, Annuska M Glas, +7 authors, Sjoerd Rodenhuis.
Breast Cancer Res Treat, 2009 Feb 14; 119(3). PMID: 19214742
Converting a breast cancer microarray signature into a high-throughput diagnostic test.
Annuska M Glas, Arno Floore, +9 authors, Laura J Van't Veer.
BMC Genomics, 2006 Nov 01; 7. PMID: 17074082    Free PMC article.
Highly Cited.
Clinical utility of the 70-gene MammaPrint profile in a Japanese population.
Makoto Ishitobi, Teodora E Goranova, +7 authors, Kikuya Kato.
Jpn J Clin Oncol, 2010 Jan 30; 40(6). PMID: 20110242
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 May 30; 351(9114). PMID: 9605801
Highly Cited.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Jolien M Bueno-de-Mesquita, Wim H van Harten, +19 authors, Sabine C Linn.
Lancet Oncol, 2007 Nov 29; 8(12). PMID: 18042430
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C W Elston, I O Ellis.
Histopathology, 1991 Nov 01; 19(5). PMID: 1757079
Highly Cited.
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 Sep 30; 352(9132). PMID: 9752815
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Breast cancer incidence and mortality trends in 16 European countries.
J L Botha, F Bray, R Sankila, D M Parkin.
Eur J Cancer, 2003 Jul 31; 39(12). PMID: 12888367
Validation of 70-gene prognosis signature in node-negative breast cancer.
J M Bueno-de-Mesquita, S C Linn, +16 authors, M J van de Vijver.
Breast Cancer Res Treat, 2008 Sep 27; 117(3). PMID: 18819002
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
Aron Goldhirsch, William C Wood, +3 authors, Hans-Jörg Senn.
J Clin Oncol, 2003 Jul 09; 21(17). PMID: 12847142
Highly Cited. Review.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
Cornelia Hauser-Kronberger, Nadia Dandachi.
J Mol Histol, 2004 Dec 23; 35(6). PMID: 15614619
NIH statement on adjuvant therapy for breast cancer.
K L Hellekson.
Am Fam Physician, 2001 May 16; 63(9). PMID: 11352296
Development of novel breast cancer recurrence prediction model using support vector machine.
Woojae Kim, Ku Sang Kim, +5 authors, Rae Woong Park.
J Breast Cancer, 2012 Jul 19; 15(2). PMID: 22807942    Free PMC article.
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients.
Hideo Shimizu, Yoshiya Horimoto, +14 authors, Mitsue Saito.
Breast Care (Basel), 2015 Jul 22; 10(2). PMID: 26195940    Free PMC article.
Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia.
Hui Miao, Mikael Hartman, +8 authors, Nirmala Bhoo-Pathy.
BMC Cancer, 2016 Oct 23; 16(1). PMID: 27769212    Free PMC article.
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gyungyub Gong, Mi Jeong Kwon, +15 authors, Young Kee Shin.
Sci Rep, 2017 Mar 30; 7. PMID: 28350001    Free PMC article.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer.
Jeeyeon Lee, Won Hwa Kim, +9 authors, Ho Yong Park.
In Vivo, 2019 Oct 31; 33(6). PMID: 31662548    Free PMC article.
Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective.
Gouri Shankar Bhattacharyya, Dinesh C Doval, +3 authors, S P Somashekhar.
JCO Glob Oncol, 2020 Jun 09; 6. PMID: 32511068    Free PMC article.
Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer.
Jeeyeon Lee, Eun Hye Lee, +9 authors, Jin Hyang Jung.
BMC Cancer, 2019 Apr 27; 19(1). PMID: 31023265    Free PMC article.